MCS-8
/ Jyong Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 20
Of
20
Go to page
1
September 16, 2025
Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention
(GlobeNewswire)
- "The randomized, placebo-controlled trial is being conducted across 20 hospitals in Taiwan, with the participation of more than 130 urologists....The Company expects to analyze the trial data following completion of the treatment period and will share results in accordance with applicable disclosure requirements."
Enrollment closed • Prostate Cancer
September 16, 2025
Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention
(GlobeNewswire)
Enrollment closed • Prostate Cancer
June 27, 2025
Detecting rs-fMRI Networks in Disorders of Consciousness: Improving Clinical Interpretability.
(PubMed, Ann Clin Transl Neurol)
- "This systematic assessment of the main rs-fMRI networks in DOC provides basic measures of functional connectivity that can enhance their interpretability in clinical practice."
Journal
December 18, 2024
Enhancing the corrosion resistance of waterborne epoxy coatings with functionalized biochar.
(PubMed, RSC Adv)
- "Electrochemical impedance spectroscopy (EIS) testing showed that after 60 days, WEP/PCNS@CMCS@8-HQ exhibited a low-frequency impedance of 1.7 × 109 Ω cm2 at the lowest frequency, with significantly improved salt spray corrosion performance compared to WEP. The study demonstrates that CMCS effectively captures Cl- and acts as a repair agent, working synergistically with the external corrosion inhibitor 8-HQ to improve the dispersion of PCNS within the WEP matrix and enhance corrosion resistance. These findings indicate that green-modified PCNS offers a promising approach to improving the corrosion resistance of coatings."
Journal
June 13, 2024
MCS-8: To Evaluate the Effect of MCS® in Prostate Cancer Prevention
(clinicaltrials.gov)
- P2 | N=702 | Active, not recruiting | Sponsor: Health Ever Bio-Tech Co., Ltd. | Trial primary completion date: Dec 2023 ➔ Dec 2024
Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
March 15, 2024
COMPARATIVE RESPONSIVENESS OF DISEASE ACTIVITY INDICES IN MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF THE UNIFI TRIAL
(DDW 2024)
- P3 | " Publicly available data from the phase 3 UNIFI induction trial (NCT0 407 36) comparing the efficacy and safety of ustekinumab versus placebo in patients with moderate-to-severe UC were obtained from Vivli (Vivli ID #7549) and Yale University Open Data Access Project (# 0 1-4848)...Overall mean baseline index scores were: MCS 8... UC disease activity indices are similarly responsive to change. Depending on trial design and measurement feasibility different instruments can be considered optimal for evaluation of efficacy. The mMS is similarly responsive to the MCS without including the physician global assessment and may be more appropriate for determining trial eligibility and defining primary endpoint whereas the UC-100 may be more appropriate for measuring treatment effect when an objective continuous measure is needed."
Retrospective data • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
May 20, 2024
Efficient Neutral H2O2 Electrosynthesis from Favorable Reaction Microenvironments via Porous Carbon Carrier Engineering.
(PubMed, Angew Chem Int Ed Engl)
- "Impressively, the optimized Pd/MCS-8 electrocatalyst in a flow cell device achieves an exceptional H2O2 yield of 15.77 mol gcatalyst-1 h-1, generating a neutral H2O2 solution with an accumulated concentration of 6.43 wt.%, a level sufficiently high for medical disinfection...Density functional theory calculations reveal that the robust interaction between Pd nanoparticles and the carbon carriers optimized the adsorption of OOH* at the carbon edge, ensuring high active 2e- process. These findings offer new insights into carbon-loaded electrocatalysts for efficient 2e- ORR in neutral media, emphasizing the role of carrier engineering in constructing favorable microenvironments and synergizing active sites."
Journal
January 25, 2024
Correlation between anxiety and decreased quality of life in patients with non-esophageal eosinophilic gastrointestinal diseases.
(PubMed, JGH Open)
- "In patients with non-EoE EGIDs, the anxiety score had a significant inverse association with the MCS-8 score. Patients with non-EoE EGIDs may have anxiety that correlates with decreased mental-health-related QOL."
HEOR • Journal • CNS Disorders • Depression • Gastroenterology • Gastrointestinal Disorder • Mental Retardation • Mood Disorders • Psychiatry
November 28, 2023
MCS-8: To Evaluate the Effect of MCS® in Prostate Cancer Prevention
(clinicaltrials.gov)
- P2 | N=702 | Active, not recruiting | Sponsor: Health Ever Bio-Tech Co., Ltd. | Trial completion date: Dec 2023 ➔ Dec 2024
Trial completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
March 24, 2023
PATIENTS WITH NON-ESOPHAGEAL EOSINOPHILIC GASTROINTESTINAL DISORDERS HAVE ANXIETY WHICH CORRELATES WITH DECREASED MENTAL HEALTH-RELATED QUALITY OF LIFE EQUIVALENT TO THAT IN PATIENTS WITH DISORDERS OF GUT-BRAIN INTERACTION
(DDW 2023)
- "MCS-8 scores were not significantly different between the non-EoE EGID and DGBI groups (46.6 [40.7, 49.8] vs. 47.2 [39.5, 49.8]), which might imply an equivalent decrease in mental health-related QOL in both groups of patients...Moreover, PCS-8 score was significantly lower in the DGBI than in the non-EoE EGID group (47.7 [42.0, 54.2] vs. 43.2 [38.4, 47.0], p = 0.029). Conclusions : Patients with non-EoE EGIDs had anxiety which correlated with decreased mental health-related QOL equivalent to that of patients with DGBI."
Clinical • HEOR • CNS Disorders • Depression • Dyspepsia • Eosinophilic Esophagitis • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Immunology • Mental Retardation • Mood Disorders • Psychiatry
March 24, 2023
CLINICAL EFFICACY, SAFETY AND TOLERABILITY OF OMILANCOR (BT-11) AS INDUCTION THERAPY FOR ACTIVE ULCERATIVE COLITIS: SEVERITY DRIVEN ANALYSIS OF A 12-WEEK PHASE 2 STUDY
(DDW 2023)
- "In this phase 2 study in patients with moderate UC, we find clear indication of efficacy for Omilancor. Low Dose Omilancor (440mg) showing the highest clinical remission and endoscopic remission rates compared to placebo. Omilancor was well tolerated and safe."
Clinical • P2 data • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mucositis • Ulcerative Colitis • LANCL2
March 13, 2023
"$SRAD Sportradar Wins Major Bid for ATP Rights https://t.co/msOTeSmCs8"
(@stock_titan)
March 05, 2023
"https://t.co/prNeqBmCs8 @azizrehman1202 @MercedesBenz @LewisHamilton @GeorgeRussell63 @AlbertBourla @MercedesAMGF1 @MercedesBenz @pfizer @Merck Ich Bin Berliner @Bundeskanzler Peace VIA Benz’s daughter: MERCEDES ……. AR 786 WINS ……."
(@azizrehman1202)
November 17, 2022
Mesoscale Mass Transport Enhancement on Well-Defined Porous Carbon Platform for Electrochemical HO Synthesis.
(PubMed, Nano Lett)
- "The performance comparison of HMCS samples in rotating ring-disk electrode and Zn-air battery together with the simulation of diffusion behavior reveals that, in low current density conditions, large surface area is preferred, but the mass transport governs the performance in high current density regions. On account of the favorable porous structure, HMCS-8 nm delivers the most excellent practical performance (166 mW cm) and performs well in the bifunctional Zn-air battery for the wastewater purification (70% RhB degraded after 2 min and 99% after 32 min)."
Journal
April 02, 2022
Preliminary construct validity of a memory concerns scale derived from a PROMIS® item bank in a spanish-speaking sample.
(PubMed, Neuropsychol Rehabil)
- "Older age was significantly associated with greater memory concerns, a relationship with age not observed with the CCS-8. As a stand-alone self-report measure, the MCS-8 appears to measure a construct distinct from general cognitive concerns that may be of interest for further research in clinical populations."
Journal
May 13, 2021
MCS-8: To Evaluate the Effect of MCS® in Prostate Cancer Prevention
(clinicaltrials.gov)
- P2; N=702; Active, not recruiting; Sponsor: Health Ever Bio-Tech Co., Ltd.; Recruiting ➔ Active, not recruiting; Trial completion date: Oct 2018 ➔ Dec 2023; Trial primary completion date: Mar 2018 ➔ Dec 2023
Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
April 22, 2021
Lack of Displacement of the Fibula is NOT Confirmation of Ankle Stability in SE Pattern Ankle Fractures.
(PubMed, J Orthop Trauma)
- "Previous work indicated that patients with an isolated SE pattern fibula fracture, a normal MCS, and ≤2mm of fibular displacement on the lateral radiograph have a high rate of ankle stability, with a positive predictive value of approaching 97%. We were unable to confirm this finding as 15% of unstable ankles had 0mm and 55% had ≤ 2mm of fibular displacement. We conclude that stability may not be inferred from a lack of fibular displacement on the lateral view in this population of patients. If stability is to be determined, it must be tested irrespective of fibular displacement on the lateral radiograph."
Journal • Musculoskeletal Diseases • Orthopedics
March 30, 2021
Changes in health-related quality of life among impoverished persons in the Free/Low-Cost Medical Care Program in Japan: Evidence from a prospective cohort study.
(PubMed, J Epidemiol)
- "Among patients using FLCMC, those who live alone may need additional support. Further study testing the generalizability of the findings is required."
Clinical • HEOR • Journal
August 11, 2020
Acute Alcohol Intoxication Impairs SHH-Gli1 Signaling and Activation of Primitive Hematopoietic Precursor Cells in the Early Stage of Host Response to Bacteremia.
(PubMed, Alcohol Clin Exp Res)
- "These data show that alcohol disrupts SHH-Gli1 signaling and HSC activation in the early stage of the granulopoietic response, which may serve as an important mechanism underlying the impairment of immune defense against bacterial infection in host excessively consuming alcohol."
Journal • CASP3 • GLI1 • KIT
February 26, 2019
Factors Associated with Health-Related Quality of Life among Jordanian Patients with Diabetic Foot Ulcer.
(PubMed, J Diabetes Res)
- "...Patients with diabetic foot ulcer had low mean DFS-SF score and low mean scores on physical and mental component summary scales (PCS8 and MCS8)...Patients with diabetic foot ulcer had low quality of life. Female gender, obesity, presence of PVD, and stressful life events were the most important factors associated with lower quality of life in patients with diabetic foot ulcer."
Clinical • HEOR • Journal
1 to 20
Of
20
Go to page
1